CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 461,858	$ 535,608
Marketable securities	186,275	158,376
Accounts receivable - trade, net	801,773	787,071
Accounts Receivable from Sanofi	118,003	104,707
Accounts receivable from Bayer HealthCare	127,720	63,189
Inventories	86,545	70,354
Deferred tax assets	36,623	44,677
Prepaid expenses and other current assets	52,252	32,952
Total current assets	1,871,049	1,796,934
Marketable securities	534,689	389,891
Property, plant, and equipment, at cost, net of accumulated depreciation and amortization	600,864	526,983
Deferred tax assets	248,454	231,878
Other assets	5,340	5,327
Total assets	3,260,396	2,951,013
Current liabilities:
Accounts payable and accrued expenses	237,935	250,896
Deferred revenue from Sanofi, current portion	12,980	12,815
Deferred Revenue - other, current portion	53,093	34,185
Facility Lease Obligations, Current	1,060	939
Total current liabilities	305,068	298,835
Deferred revenue from Sanofi	73,694	76,522
Deferred Revenue - other	128,539	107,677
Facility lease obligations	203,380	184,258
Convertible senior notes	326,673	320,315
Other long-term liabilities	11,794	11,330
Total liabilities	1,049,148	998,937
Stockholders' equity:
Preferred Stock	0	0
Additional paid-in capital	2,236,931	2,045,857
Accumulated deficit	(27,249)	(92,692)
Accumulated other comprehensive income (loss)	1,465	(1,188)
Total stockholders' equity	2,211,248	1,952,076
Total liabilities and stockholders' equity	3,260,396	2,951,013
Class A Stock
Stockholders' equity:
Common stock	2	2
Common Stock
Stockholders' equity:
Common stock	$ 99	$ 97